NanoEcho
0.07 SEK
-3.23 %
Less than 1K followers
NANECH
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-3.23 %
+6.46 %
-37.59 %
-23.01 %
-78.28 %
-40.22 %
-
-
-57.73 %
NanoEcho is active in healthcare, with a main focus in rectal cancer diagnostics. The company is active in the clinical stage, where a new diagnostic method is being developed to determine whether early rectal cancer has spread to nearby lymph nodes. The method aims to provide a correct diagnosis and individualized treatment. NanoEcho was founded in 2013 and has its headquarters in Lund.
Read moreMarket cap
19.3M SEK
Turnover
2.44K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
12/2
2026
Annual report '25
30/4
2026
Interim report Q1'26
28/5
2026
General meeting '26
All
Press releases
3rd party
ShowingAll content types
Läkemedelsverkets godkännande för användning av NEP-01 i Proof of Concept-studien enligt planerat studieupplägg
Montering av forskningssystem till Lunds universitet slutförd
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools